Guizhou Xinbang Pharmaceutical Co., Ltd.
Symbool: 002390.SZ
SHZ
3.89
CNYMarktprijs vandaag
32.8887
Koers/Winst Verhouding
-2.3022
Koers/Winst Groei Verhouding
7.06B
MRK Kapitalisatie
- 0.01%
DIV Rendement
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390-SZ) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 899.2 | 624.6 | 1776.4 | |||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.net-receivables | 0 | 3870.6 | 4011.3 | 3466.8 | |||||||||||||||||
balance-sheet.row.inventory | 0 | 1032.7 | 935.7 | 843.4 | |||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 3.7 | 4.7 | 4.6 | |||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 5806.2 | 5576.4 | 6091.1 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 2671.7 | 2705.9 | 2323.2 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 607.3 | 607.3 | 605.5 | |||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 204.4 | 217.6 | 219.6 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 811.7 | 825 | 825.1 | |||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 343.8 | 347.4 | 223 | |||||||||||||||||
balance-sheet.row.tax-assets | 0 | 62.4 | 55.6 | 46.5 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 97.2 | 118.4 | 153.2 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 3986.9 | 4052.3 | 3571 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 0 | 9793.1 | 9628.6 | 9662.2 | |||||||||||||||||
balance-sheet.row.account-payables | 0 | 977.2 | 993.4 | 788.6 | |||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 1345.8 | 1362.3 | 3382.5 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 33.3 | 37.4 | 32.2 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 22 | 24.8 | 24.5 | |||||||||||||||||
Deferred Revenue Non Current | 0 | 18.9 | 20.4 | 22.9 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 330.6 | 6.5 | 4.6 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 41.2 | 45.5 | 23.2 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 22 | 24.8 | 24.5 | |||||||||||||||||
balance-sheet.row.total-liab | 0 | 2728 | 2800.1 | 4493.7 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0 | 1943.9 | 2027.2 | 1667.2 | |||||||||||||||||
balance-sheet.row.retained-earnings | 0 | 373.2 | 271.5 | 28 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 189.6 | 102.7 | 57.3 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 4301.7 | 4218.4 | 3165.9 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 6808.5 | 6619.8 | 4918.3 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 9793.1 | 9628.6 | 9662.2 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 256.6 | 208.7 | 250.2 | |||||||||||||||||
balance-sheet.row.total-equity | 0 | 7065 | 6828.5 | 5168.5 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||||
Total Investments | 0 | 343.8 | 347.4 | 223 | |||||||||||||||||
balance-sheet.row.total-debt | 0 | 1367.8 | 1387.1 | 3382.5 | |||||||||||||||||
balance-sheet.row.net-debt | 0 | 468.6 | 762.5 | 1606.1 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 268.4 | 374 | 220.6 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 243.5 | 247.3 | 231.6 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -6.8 | -9.1 | 6.4 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 31.5 | 6 | -6.4 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -117.1 | -338.6 | 74.8 | |||||||||||||||||
cash-flows.row.account-receivables | 0 | 95 | -609.8 | 348.1 | |||||||||||||||||
cash-flows.row.inventory | 0 | -97 | -92.3 | 150.9 | |||||||||||||||||
cash-flows.row.account-payables | 0 | -108.3 | 372.6 | -430.6 | |||||||||||||||||
cash-flows.row.other-working-capital | 0 | -6.8 | -9.1 | 6.4 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 171.3 | 178.4 | 215 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -158.8 | -253.8 | -138.1 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 1.6 | -295.5 | 566.1 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -12.4 | -1719.6 | -1516.5 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 51 | 1523.6 | 1494.7 | |||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0.5 | 0.9 | 1.7 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -118 | -744.3 | 408 | |||||||||||||||||
cash-flows.row.debt-repayment | 0 | -2019.5 | -4257 | -3561.4 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 86.2 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | -86.2 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | -168.4 | -230.3 | -197.6 | |||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 1998.4 | 3576.7 | 3171.8 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -189.4 | -910.6 | -587.2 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 2.3 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 283.4 | -1196.9 | 565.2 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 797 | 513.7 | 1710.6 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 513.7 | 1710.6 | 1145.4 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 590.8 | 458 | 742.1 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -158.8 | -253.8 | -138.1 | |||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 432 | 204.2 | 604 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 6350 | 6471.9 | 5845.6 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 5133.1 | 5119.4 | 4593.5 | |||||||||||||||||
income-statement-row.row.gross-profit | 0 | 1217 | 1352.5 | 1252.1 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 0 | 292 | 297.8 | 268.3 | |||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 836.4 | 787.1 | 802.1 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 5969.5 | 5906.5 | 5395.7 | |||||||||||||||||
income-statement-row.row.interest-income | 0 | 13.5 | 14 | 15.4 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 51.8 | 100.2 | 99.6 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -114.4 | -30.4 | -162.5 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 292 | 297.8 | 268.3 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -114.4 | -30.4 | -162.5 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 51.8 | 100.2 | 99.6 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 243.5 | 347.7 | 231.6 | |||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | 0 | 427.8 | 451.5 | 429.9 | |||||||||||||||||
income-statement-row.row.income-before-tax | 0 | 313.4 | 421.1 | 267.5 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 45 | 47.2 | 46.9 | |||||||||||||||||
income-statement-row.row.net-income | 0 | 224.5 | 374 | 173.5 |
Vaak gestelde vragen
Wat is Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) totale activa?
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) totale activa is 9793091573.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.190.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.037.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 0.053.
Wat is Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) nettowinst (netto-inkomen)?
De nettowinst is 224479086.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 1367777175.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 836448131.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.